Sandbox sc

Jump to navigation Jump to search

Anaplasmosis

  • Human granulocytic anaplasmosis, suspected or symptomatic [1]
  • Preferred regimen: Doxycycline 100 mg orally bid (or intravenously for those patients unable to take an oral medication) for 10 days
  • Alternative regimen: Rifampin 300 mg orally bid for 7–10 days (For patients with mild illness due to HGA who are not optimally suited for doxycycline treatment because of a history of drug allergy, pregnancy, or age <8 years)
  • Pediatric regimen: Doxycycline 4 mg/kg per day in 2 divided doses (maximum of 100 mg per dose) given orally (or intravenously for children unable to take an oral medication); Rifampin 10 mg/kg bid for children (maximum of 300 mg per dose) (For children age <8 years without Lyme disease)
NOTE (1): Children ≥8 years of age may be treated with a 10-day course of Doxycycline; For severely ill children <8 years of age without concomitant Lyme disease, the panel recommended an abbreviated treatment course of 4–5 days
NOTE (2): If the patient has concomitant Lyme disease, then Amoxicillin 50 mg/kg per day in 3 divided doses (maximum of 500 mg per dose) OR Cefuroxime axetil 30 mg/kg per day in 2 divided doses (maximum of 500 mg per dose) should be initiated at the conclusion of the course of Doxycycline to complete a 14-day total course of antibiotic therapy
NOTE: Rifampin is not effective therapy for Lyme disease, patients coinfected with B. burgdorferi should also be treated with Amoxicillin OR Cefuroxime axetil

Brucellosis

  • Uncomplicated brucellosis
  • Complications of brucellosis
  • For children eight years of age and older
  • For children less than eight years of age

Ehrlichiosis

Tularemia

Typhoid fever

References

  1. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS; et al. (2006). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clin Infect Dis. 43 (9): 1089–134. doi:10.1086/508667. PMID 17029130.